Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients
- PMID: 25559810
- DOI: 10.1200/JCO.2014.57.6967
Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients
Abstract
Purpose: High-grade T1 (HGT1) bladder cancer is the highest risk subtype of non-muscle-invasive bladder cancer, with highly variable prognosis, poorly understood risk factors, and considerable debate about the role of early cystectomy. We aimed to address these questions through a meta-analysis of outcomes and prognostic factors.
Methods: PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and American Society of Clinical Oncology abstracts were searched for cohort studies in HGT1. We pooled data on recurrence, progression, and cancer-specific survival from 73 studies.
Results: Five-year rates of recurrence, progression, and cancer-specific survival were 42% (95% CI, 39% to 45%), 21% (95% CI, 18% to 23%), and 87% (95% CI, 85% to 89%), respectively (56 studies, n = 15,215). In the prognostic factor meta-analysis (33 studies, n = 8,880), the highest impact risk factor was depth of invasion (T1b/c) into lamina propria (progression: hazard ratio [HR], 3.34; P < .001; cancer-specific survival: HR, 2.02; P = .001). Several other previously proposed factors also predicted progression and cancer-specific survival (lymphovascular invasion, associated carcinoma in situ, nonuse of bacillus Calmette-Guérin, tumor size > 3 cm, and older age; HRs for progression between 1.32 and 2.88, P ≤ .002; HRs for cancer-specific survival between 1.28 and 2.08, P ≤ .02).
Conclusion: In this large analysis of outcomes and prognostic factors in HGT1 bladder cancer, deep lamina propria invasion had the largest negative impact, and other previously proposed prognostic factors were also confirmed. These factors should be used for prognostication and patient stratification in future clinical trials, and depth of invasion should be considered for inclusion in TNM staging criteria. This meta-analysis can also help define selection criteria for early cystectomy in HGT1 bladder cancer, particularly for patients with deep lamina propria invasion combined with other risk factors.
© 2015 by American Society of Clinical Oncology.
Comment in
-
Reply to K. Lu.J Clin Oncol. 2015 Aug 20;33(24):2716-7. doi: 10.1200/JCO.2015.62.5301. Epub 2015 Jul 20. J Clin Oncol. 2015. PMID: 26195703 No abstract available.
-
Depth of Invasion in High-Grade T1 Bladder Cancer: Added Value In Timely Cystectomy?J Clin Oncol. 2015 Aug 20;33(24):2715-6. doi: 10.1200/JCO.2015.62.2712. Epub 2015 Jul 20. J Clin Oncol. 2015. PMID: 26195712 No abstract available.
Similar articles
-
Prognostic value of the lymphovascular invasion in high-grade stage pT1 bladder cancer.Clin Genitourin Cancer. 2013 Jun;11(2):182-8. doi: 10.1016/j.clgc.2012.10.002. Epub 2012 Dec 29. Clin Genitourin Cancer. 2013. PMID: 23276589
-
Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients.Eur Urol. 2005 Aug;48(2):231-8; discussion 238. doi: 10.1016/j.eururo.2005.04.013. Eur Urol. 2005. PMID: 15963635
-
Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.J Urol. 2013 Jun;189(6):2069-76. doi: 10.1016/j.juro.2012.11.120. Epub 2012 Nov 28. J Urol. 2013. PMID: 23201497
-
Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients.J Urol. 2012 Dec;188(6):2046-54. doi: 10.1016/j.juro.2012.08.017. Epub 2012 Oct 18. J Urol. 2012. PMID: 23083867 Review.
-
Determining the role of cystectomy for high-grade T1 urothelial carcinoma.Urol Clin North Am. 2013 May;40(2):233-47. doi: 10.1016/j.ucl.2013.01.003. Epub 2013 Feb 16. Urol Clin North Am. 2013. PMID: 23540781 Review.
Cited by
-
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis.World J Urol. 2020 Jun;38(6):1437-1449. doi: 10.1007/s00345-019-02936-y. Epub 2019 Sep 6. World J Urol. 2020. PMID: 31493109 Free PMC article.
-
High-Grade Non-Muscle Invasive Bladder Cancer: When to Move to Early Radical Cystectomy?Cureus. 2021 Nov 9;13(11):e19399. doi: 10.7759/cureus.19399. eCollection 2021 Nov. Cureus. 2021. PMID: 34926001 Free PMC article.
-
Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage era.Transl Androl Urol. 2023 Jun 30;12(6):960-966. doi: 10.21037/tau-22-772. Epub 2023 May 30. Transl Androl Urol. 2023. PMID: 37426602 Free PMC article.
-
Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.Eur Urol Focus. 2017 Dec;3(6):577-583. doi: 10.1016/j.euf.2017.06.004. Epub 2017 Jul 13. Eur Urol Focus. 2017. PMID: 28753816 Free PMC article.
-
Artificial Intelligence in Digital Pathology for Bladder Cancer: Hype or Hope? A Systematic Review.Cancers (Basel). 2023 Sep 12;15(18):4518. doi: 10.3390/cancers15184518. Cancers (Basel). 2023. PMID: 37760487 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical